Dr Kiran K Jagarlamudi of AroCell AB made an oral presentation today at the International Society of Oncology and Biomarkers in Chicago entitled “Evaluation of an improved version of the AroCell TK 210 ELISA for determining thymidine kinase 1 protein levels in serum samples”.
Dr Jagarlamudi concluded his presentation by stating that using the improved zero calibrator matrix increased sensitivity of AroCell TK 210 ELISA so that TK1 protein could be detected in sera from more than 95% of healthy persons compared to approximately 50% when using the earlier zero calibrator matrix. He also concluded by stating that increasing the accuracy of determining TK1 levels in healthy samples offers the potential for better discrimination between healthy and pathological resulting in increased clinical value of the assay.
His presentation was well received by the audience, and several participants contacted AroCell representatives in the booth following the presentation, to discuss research opportunities in different clinical areas.
A copy of the abstract can be found in the enclosed pdf file ISOBM poster_a4_r21
A link to the publisher is enclosed where the study may be found listed as number 135 on http://link.springer.com/article/10.1007/s13277-016-5287-4/fulltext.html